Victoria Langowska , 2025-04-14 16:24:00
April 14, 2025
1 min watch
In this video, Robert DeBernardo, MD, discusses
his research on hyperthermic intraperitoneal chemotherapy among patients with ovarian cancer and underlying kidney disease, which he presented at Society of Gynecologic Oncology Annual
Meeting on Women’s Cancer.
DeBernardo, section head of the department of obstetrics and
gynecology and Women’s Health Institute at Cleveland Clinic, explains that hyperthermic
intraperitoneal chemotherapy (HIPEC) with cisplatin appears safe in this
patient population.
“What we’ve shown in our data are that [among] people who have
underlying kidney disease, it’s safe to give HIPEC with cisplatin, which is the
drug that causes that kidney injury,” DeBernardo said. “We’ve shown outcomes
don’t change: We don’t make their renal failure worse in the short- or long-term.”